Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights February 23, 2026 Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full year 2026 net cash used in operating and investing activities to be $50 to $55 million and expects to end the year with approximately $255 million in cash (midpoint). Financial guidance does not include the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026 Roche initiated the Phase 3 PARAISO trial evaluating prasinezumab in early-stage Parkinson’s disease in 4Q 2025; primary completion expected in 2029 Novo Nordisk initiated the Phase 3 CLEOPATTRA trial evaluating coramitug in ATTR amyloidosis with cardiomyopathy in 4Q 2025; primary completion expected in 2029 Bristol Myers Squibb fully enrolled the Phase 2 TargetTau-1 trial evaluating BMS-986446 in early Alzheimer’s disease with primary completion expected in 1H 2027, completed a Phase 1 trial evaluating a subcutaneous formulation of BMS-986446 and obtained Fast Track designation from the U.S. FDA for BMS-986446 for the treatment of Alzheimer’s disease Prothena presented preclinical data on its TDP-43 CYTOPE® program at Neuroscience 2025 (SfN) and at the International Symposium on ALS/MND demonstrating the potential of Prothena’s CYTOPE® technology to target intracellular disease pathways At the Extraordinary General Meeting on November 19, 2025 Prothena obtained shareholder approval to reduce share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb
Options Announces 15 Consecutive Years of SOC Compliance, Underlying Its Commitment to Delivering Secure Reliable Solutions February 23, 2026 Options Technology (Options), the leading provider of IT infrastructure to global financial institutions, today announced that it has achieved SOC compliance for the 15th consecutive year, adhering to Type 2 SOC 1 & ISAE 3402, Type 2 SOC 2, and Type 2 SOC 3 standards. Danny Moore, President and CEO at Options said, “From the [...]
Westlake Epoxy Expands Distribution Relationship with Brenntag to India February 23, 2026 Westlake Corporation (NYSE: WLK) today announced that Westlake Epoxy will expand its long‑standing distribution relationship with Brenntag to South and West India. The agreement builds on a successful collaboration across Europe, North and South America, and Southeast Asia, extending Westlake Epoxy’s reach into one of the world’s fastest‑growing coatings, adhesives and construction markets. Under the [...]
ActiveCampaign Backs Autonomous Marketing with Results Guarantee February 23, 2026 The company becomes first in category to guarantee marketing outcomes, signaling strong platform performance & commitment to customer success
BAE Systems Announces 2025 Full Year Results February 23, 2026 Charles Woodburn, Chief Executive, said: “Our results highlight another year of strong operational and financial performance, thanks to the outstanding dedication of our employees. In a new era of defence spending, driven by escalating security challenges, we’re well positioned to provide both the advanced conventional systems and disruptive technologies needed to protect the nations we [...]
AlgoSec Posts 37% YoY New Business Growth in 2025 as Enterprises Prioritise Application-Centric Security February 23, 2026 Over 90% gross dollar retention and 37% year-over-year new business growth reflect demand for visibility across complex hybrid environments
Jensen Partners Named Recruitment Company of the Year: Investor Relations & Asset Raising at the 2026 Private Equity Wire® European Awards February 23, 2026 Recognition highlights the firm’s leadership in capital formation and investor relations recruitment across European private markets
INCERGO S.A. Announces Share Capital Increase and Strategic Shareholding with Visual Semiconductor February 23, 2026 INCERGO S.A. (Symbol: ICG) announces that, effective February 19, 2026, its issued share capital has increased from 5,060,000 to 151,283,387 registered ordinary shares. The issuance of 146,223,387 new shares has been duly registered and is effective on the Vienna Stock Exchange as of today. The company announced further progress in its merger with Visual Semiconductor [...]
Capitolis to Acquire 20 Gates Management’s U.S. Secured Financing Platform to Expand its Capital Marketplace February 20, 2026 Strategic acquisition enables Capitolis to deliver U.S. secured financing through its Capital Marketplace, broadens client base, and adds veteran industry talent
Telekom Srbija Group Announces Platinum Sponsorship of EXPO 2027 Belgrade February 20, 2026 Telekom Srbija to power EXPO 2027 and unveil dedicated pavilion showcasing its technology ecosystem